Company: CERO
Filing Date: 2025-09-05
Form Type: 424B3
Source: 0001213900-25-085127
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-09-05
Form: 424B3
Chunk 2
---
17 CFR 240.14a-12) |

| ☐ | Pre-commencement                                                                      
 communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |

| ☐ | Pre-commencement                                                                      
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                                                                  |     | Trading Symbol(s) |     | Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share                                            |     | CERO              |     | Nasdaq Capital Market                     |
| Warrants, each warrant exercisable for one two-thousandth of a share of Common Stock |     | CEROW             |     | Nasdaq Capital Market                     |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On September 5, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), issued a press release announcing that the Company received Fast Track Designation from the U.S. Food and Drug Administration in relation to the Company’s lead investigational compound, CER-1236 for Acute Myeloid Leukemia (AML). A copy of the press release is attached herewith as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

| Exhibit 
 No.     
 99.1    |     | Description                                                            
 Press release, dated September 5, 2025.                                |
|:--------|:----|:-----------------------------------------------------------------------|
| 104     |     | Cover                                                                  
 Page Interactive Data File (embedded within the Inline XBRL document). |

<div align='center'>1

SIGNATURE</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the